Rigel Pharmaceuticals : Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 /PRNewswire/ -- Eli Lilly and Company and Rigel Pharmaceuticals, Inc. today announced a global exclusive license agreement and... | February 22, 2021
Source: marketscreener.com